disorder of thought psychotic disorder
Conditions
Interventions
Treatment plans that include cognitive adaptation training are based on two
dimensions: 1) the patient*s level of apathy versus disinhibition, and 2) the
patient*s level of impairment in executive f
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Schizophrenia or schizo-affective disorder according to DSM-IV criteria, age between 21 and 65 years old, fluent in Dutch, cognitive impairment, problems in daily functioning (GAF-D
Exclusion criteria
Exclusion criteria: Premorbid IQ
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prior to the baseline-assessment (T0), patients will be asked to participate in CAT. Effect measurements will be carried out after 4 months (T4) and after 8 months (T8). It is still unknown which outcome measurements will adress the research questions (mentioned under Objectives) best. Therefore, multiple outcome measures will be included in this study. In a recent study by Velligan et al. (2008), an effect size of Cohen's D > 1.0 was reported. Therefore, we expect the GAF-D to be most sensitive for change in daily functining. Furthermore, the Multnomah Community Ability Scale (MCAS) and the Negative Symptoms Assessment (NSA) will be assessed. These semi-structured interviews are also used in the American CAT-studies. The MCAS contains 17 items on domains interfering with functioning, independence & acceptation, social competence and behavioral problems. From the NSA, only the subscale motivation will be assessed, which contains items on self care, activities and sense of purpose. To adress the second research question (feasability of CAT as a nursing intervention), the Quality Assurance Measures Form (QAMF) and the Client Satisfaction Questionnaire (CSQ) will be assessed. The QAMF is a treatment fidelity form, also used in the studies by Velligan et al., and is being scored from supervision sessions and tape recordings of the CAT-session. The patient will be assessed with an amended version of the CSQ, to evaluate client satisfaction. Furthermore, we expect empowerment to be an important outcome measure. The Mental Health Confidence Scale (MHCS) will be used to adress this, for this scale has proven to be sensitive for change (Castelein et al., 2008). An overview of all outcome measurements used in this study can be found below, and under 'secondary study parameters'. Effect measures (T0, T4 en T8) Total duration: 1* hours Daily functioning: 1. Global Assessment of Functioning - Disabilities (American Psychiatric Association, 1994), sc | — |
Secondary
| Measure | Time frame |
|---|---|
| Daily functioning: 2. Multnomah Community Ability Scale (Barker), semi-gestructureerd interview 3. Negative Symptom Assessment, subscale motivation (Alphs), semi-structured interview 4. Social Functioning Scale (Birchwood et al., 1990), self-report and proxy 5. Goal Attainment Scale (Steinbook et al., 1977), semi-structured interview Well being: 1. Mental Health Confidence Scale (Carpinello et al., 2000), self-report 2. Manchester Short Assessment of Quality of Life (Priebe et al., 1999), self-report 3. EuroQoL - 5D (König et al., 2007), self-report Performance based tasks: 1. Mini Mental State Examination (Roper et al., 1996) 2. Frontal Assessment Battery (Dubois et al., 2000) 3. Test of Adaptive Behavior for Schizophrenia, subtest Self-Medication (Velligan et al., 2007) Treatment evaluation: 1. Quality Assurance Measures Form (Velligan, unpublished) 2. Client Satisfaction Questionnaire (CAT-version) (de Brey, 1983) | — |
Countries
Netherlands
Outcome results
None listed